P. Daley-Yates

Bioavailability of fluticasone propionate and mometasone furoate aqueous nasal sprays

Y. Yin, C. Ng, P. Daley-Yates, 2004, European Journal of Clinical Pharmacology.

Systemic bioavailability of fluticasone propionate administered as nasal drops and aqueous nasal spray formulations.

R. Baker, P. Daley-Yates, 2008, British journal of clinical pharmacology.

From hydrofluoroalkane pressurized metered dose inhalers (pMDIs) and comparability with chlorofluorocarbon pMDIs.

L. Squassante, L. Ziviani, P. Daley-Yates, 2000, Respiratory medicine.

Pulmonary indoleamine 2,3-dioxygenase activity and its significance in the response of rats, mice, and rabbits to oxidative stress.

L. L. Smith, A. Powell, P. Daley-Yates, 1988, Toxicology and applied pharmacology.

Dose responses for topical efficacy and systemic activity, dose equivalence and relative therapeutic index for fluticasone furoate (FF), fluticasone propionate (FP) and budesonide (BUD) in asthmatic subjects

Dave Singh, P. Daley-Yates, N. Brealey, 2019, Pneumologie.

Cushing's syndrome and severe adrenal suppression in patients treated with ritonavir and inhaled nasal fluticasone.

S. Robinson, D. Churchill, S. Waldron, 1999, Sexually transmitted infections.